(Q24243205)

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Depot naltrexone: long-lasting antagonism of the effects of heroin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Plasma concentrations during naltrexone implant treatment of opiate-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Kinetics of a naltrexone sustained-release preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Clinical evaluation of a naltrexone sustained-release preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

A multicentre study to introduce naltrexone for opiate dependence in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

A new approach to preventing relapse in opiate addicts: a psychometric evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Extended-release intramuscular naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Depot naltrexone in lieu of incarceration: a behavioral analysis of coerced treatment for addicted offenders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

A sustained release depot for narcotic antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Mental health outcomes following naltrexone implant treatment for heroin-dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Fatal opiate overdose following regimen changes in naltrexone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Addiction pharmacotherapy 2000: new options, new challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Prospects, Problems, Side Effects, and Safety of Narcotic Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Sustained-release naltrexone: novel treatment for opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone pharmacotherapy for opioid dependent federal probationers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Overcoming opioid blockade from depot naltrexone (Prodetoxon).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Improvement in naltrexone treatment compliance with contingency management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Evidenced-based treatment of opioid-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Pharmacokinetic Study of the New Domestic Hypodermic Form of Naltrexone: Prodetoxon Depot Tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

Lactic/glycolic acid polymers as narcotic antagonist delivery systems

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

Naltrexone implant and blood naltrexone levels over pregnancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

Using naltrexone implants in the management of the pregnant heroin user

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

Use of oral and implantable naltrexone in the management of the opioid impaired physician

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

A comparison of oral and implant naltrexone outcomes at 12 months.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006140.PUB2

7 January 2021

10.1002/14651858.CD006140.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

18425938

1 reference

Consolidated OpenCitations Corpus – April 2017